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ABSTRACT
The syndrome of microangiopathic hemolysis associated with renal failure, neurologic impairment, or both is
a recognized complication of hematopoietic stem cell transplantation. This entity is often called hemolytic
uremic syndrome (HUS) or thrombotic thrombocytopenic purpura (TTP), yet it is clear that the pathophys-
iology of transplant-associated HUS/TTP is different from that of classic HUS or TTP. Furthermore, the
incidence of this syndrome varies from 0.5% to 76% in different transplant series, primarily because of the lack
of a uniform definition. The toxicity committee of the Blood and Marrow Transplant Clinical Trials Network
has reviewed the current literature on transplant-related HUS/TTP and recommends that it be henceforth
renamed posttransplantation thrombotic microangiopathy (TMA). An operational definition for TMA based on
the presence of microangiopathic hemolysis and renal and/or neurologic dysfunction is proposed. The primary
intervention after diagnosis of TMA should be withdrawal of calcineurin inhibitors. Plasma exchange, although
frequently used in this condition, has not been proven to be effective. In the absence of definitive trials, plasma
exchange cannot be considered a standard of care for TMA. It is hoped that these positions will improve the
identification and reporting of this devastating complication after hematopoietic stem cell transplantation and
facilitate future clinical studies for its prevention and treatment.
© 2005 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
Thrombotic microangiopathy (TMA) syndromes,
resenting as hemolytic uremic syndrome (HUS) or
hrombotic thrombocytopenic purpura (TTP), are
ell-recognized complications of hematopoietic stem
ell transplantation (HSCT). The reported incidence
f TMA after allogeneic HSCT varies from 0.5% to
6% [1-5]. In a recent literature review including 35
ublished articles involving more than 5423 allogeneic c
B&MTSCT recipients, George et al. [6] identiﬁed 447
8.2%) cases of posttransplantation TMA, with a me-
ian mortality of 75% within 3 months of the diag-
osis. The large variability in published incidence
rises from the fact that there are no uniformly ac-
epted diagnostic criteria for this clinical syndrome.
ecause patients after HSCT often develop anemia,
hrombocytopenia, fever, renal dysfunction, and frag-
ented red blood cells (RBCs) from many competing
auses, a diagnosis of TMA in this population is often
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5ery difﬁcult to establish and requires a high index of
linical suspicion. However, agreement on diagnostic
riteria will be crucial to accurately assess the effects of
ew agents (eg, new calcineurin inhibitors) on the
ncidence of this disorder and to study interventions
or its prevention or treatment.
In an effort to establish guidelines for reporting
dverse events after HSCT in clinical trials facilitated
y the Blood and Marrow Transplant Clinical Trials
etwork (BMT CTN), the BMT CTN Committee
n Transplant Toxicity convened to review the cur-
ent knowledge about TMA as a transplantation com-
lication and to propose an operational deﬁnition for
his clinical syndrome.
LINICAL FEATURES
The classic presentation of TMA is the relatively
cute onset of anemia and thrombocytopenia with
vidence of RBC fragmentation in the peripheral
lood smear. An associated increase in the serum lactic
ehydrogenase (LDH), with concomitant acute renal
ysfunction, occurs in the large majority of patients.
eurologic deﬁcits, including but not restricted to
onfusion and seizures, occur in up to half the cases in
ome series. The clinical spectrum of TMA is broad
nd can range from life-threatening neurologic or
enal complications requiring plasma exchange, dial-
sis, or both to asymptomatic anemia with schistocy-
osis and mild renal dysfunction. The onset of post-
ransplantation TMA usually occurs within the ﬁrst
00 days after stem cell infusion. In a reported series
rom the European Blood and Marrow Transplant
roup, the median onset was 44 days after HSCT,
ith a range of 13 to 319 days [4]. Clinical hemor-
hage, graft-versus-host disease (GVHD), and infec-
ions were common causes of death in this population.
everal reports have suggested that infections from
spergillus or viruses such as cytomegalovirus, adeno-
irus, human herpesvirus 6, and parvovirus B19 can in
hemselves lead to microangiopathic hemolysis and
herefore mimic the diagnosis of TMA [7-14].
In HSCT series, severe TMA is variably associ-
ted with advanced recipient age, female sex, unre-
ated or HLA-mismatched donor grafts, GVHD, viral
r fungal infections, and use of calcineurin inhibitors
uch as cyclosporine [1-5]. Investigators at the Dana-
arber Cancer Institute have also reported an in-
reased risk for TMA in patients who receive siroli-
us with tacrolimus as GVHD prophylaxis [15].
EFINITION OF TMA
The committee proposes that the term posttrans-
lantation TMA should be used to describe HUS and
TP associated with stem cell transplantation, be-
72ause available data indicate an etiology and natural
istory different from those with HUS/TTP outside
he HSCT setting. The participants agree that it is
mportant to have a uniform operational deﬁnition for
MA so that future descriptive or interventional stud-
es can incorporate comparably deﬁned patient popu-
ations. Current criteria used to deﬁne TMA in the
iterature are highly varied and confusing. For exam-
le, in the literature review of HUS/TTP after HSCT
ublished by George et al. [6], 28 sets of diagnostic
riteria were used in the 35 articles included in the
eview. Among these articles, the most frequently
ited diagnostic features, in descending frequency,
ere (1) RBC fragmentation, (2) increased serum
DH, (3) decreased platelet count, (4) renal failure,
nd (5) neurologic dysfunction. Less commonly in-
luded criteria were negative tests for disseminated
ntravascular coagulation and negative Coombs test
esults. The last 2 features were included in the re-
orts published from the European Blood and Mar-
ow Transplant Group and Gruppo Italiano Trapi-
nto Midollo Osseo [3,4]. The committee also
eviewed the deﬁnition used in a recent retrospective
nalysis of TMA among patients receiving tacrolimus
nd sirolimus conducted by Henry et al. [15] at the
ana-Farber Cancer Institute.
After consideration of these data, the committee
roposes the following operational deﬁnition of TMA
or validation in future prospective trials (Table 1): (1)
BC fragmentation with 2 schistocytes per high-
ower ﬁeld on peripheral smear; (2) concurrent in-
reased serum LDH above institutional baseline; (3)
oncurrent renal and/or neurologic dysfunction with-
ut other explanations, where renal dysfunction is
eﬁned as either a doubling of serum creatinine from
aseline, where baseline is the creatinine taken before
ydration and just before initiation of the condition-
ng regimen, or a 50% decrease in creatinine clearance
rom baseline; and (4) negative direct and indirect
oombs test results. The panel decided against using
hrombocytopenia as a diagnostic criterion because
ransplant recipients often have low platelet counts
rom various causes during the early posttransplanta-
ion period.
able 1. BMT CTN Toxicity Committee Consensus Deﬁnition for
MA
. RBC fragmentation and >2 schistocytes per high-power field
on peripheral smear
. Concurrent increased serum LDH above institutional
baseline
. Concurrent renal* and/or neurologic dysfunction without
other explanations
. Negative direct and indirect Coombs test results
Doubling of serum creatinine from baseline (baseline  creatinine
before hydration and conditioning) or 50% decrease in creati-
nine clearance from baseline.
Si
l
s
n
c
g
n
e
t
m
t
n
p
t
f
t
f
T
m
r
d
e
i
a
r
p
t
p
p
w
i
s
p
H
N
a
H
c
t
t
C
d
n
t
i
w
l
s
g
T
s
p
d
d
t
w
t
r
s
h
s
t
T
a
a
g
t
b
l
m
e
p
c
e
r
a
T
M
G
G
G
G
U
T
P
S
S
D
L
P
I
U
R
F
R
S
N
Consensus Summary: TMA after HSCT
BTAGING OF TMA
Pettitt and Clark [1] previously proposed classify-
ng posttransplantation TMA into 4 distinct but over-
apping subtypes based on clinical features and the
everity of the clinical course: (1) multifactorial fulmi-
ant TMA, (2) conditioning-associated HUS, (3) cy-
losporine-associated nephrotoxicity with microan-
iopathic hemolysis, and (4) cyclosporine-associated
eurotoxicity with microangiopathic hemolysis. How-
ver, subcategorization of TMA cases into these sub-
ypes is difﬁcult because of overlapping features in
any cases. For example, according to this classiﬁca-
ion scheme, patients with cyclosporine-associated
ephrotoxicity or neurotoxicity with microangio-
athic hemolysis would have clinical features similar
o those with multifactorial fulminant TMA, except
or the severity of the clinical outcome. Consequently,
his classiﬁcation does not seem to be a useful system
or prospectively staging patients with developing
MA.
Zeigler et al. [2] proposed using a TTP index as a
ethod of scoring clinical severity. The TTP index
epresents the ratio of serum LDH to platelet count at
iagnosis; a ratio of 20 indicates severe TTP. How-
ver, this system is subject to variability from differing
nstitutional normal laboratory values for serum LDH
nd also from the fact that platelet counts are often
educed for reasons other than TTP in the posttrans-
lantation patient population. Uderzo et al. [16] applied
he TTP index in their retrospective series of 28 cases of
ediatric posttransplantation TTP. They found that
eak serum LDH, but not the TTP index at diagnosis,
as signiﬁcantly associated with mortality.
The committee concluded that there are currently
nsufﬁcient data to endorse a staging/grading system
peciﬁc for posttransplantation TMA. Instead, the
articipants suggest that the severity of TMA after
SCT should be assessed according to the current
ational Cancer Institute Common Toxicity Criteria
dverse event grading system, as shown in Table 2.
owever, the committee agrees that a minor modiﬁ-
ation to this system is necessary to render it consis-
ent with the currently proposed operational deﬁni-
ion. Speciﬁcally, patients with Common Toxicity
able 2. Common Toxicity Criteria for BMT Thrombotic
icroangiopathy
rade 1 Evidence of RBC destruction (schistocytosis)
without clinical consequences
rade 2 Evidence of RBC destruction with increased
creatinine <3 times the ULN
rade 3 Evidence of RBC destruction with creatinine
>3 times the ULN not requiring dialysis
rade 4 Evidence of RBC destruction with renal failure
requiring dialysis, and/or encephalopathycLN indicates upper limit of normal.
B&MTriteria grade 1 will not meet the currently proposed
eﬁnition for TMA because they do not have renal or
eurologic dysfunction. The committee believes that
his exclusion is justiﬁable because some schistocytosis
s common after HSCT and that this isolated ﬁnding
ithout associated organ dysfunction is likely to have
ittle clinical signiﬁcance. On the basis of these con-
iderations, only Common Toxicity Criteria severity
rades 2 to 4 should be applicable in reporting TMA.
HERAPY FOR POSTTRANSPLANTATION TMA
There was consensus that calcineurin inhibitors
hould be discontinued after diagnosis of posttrans-
lantation TMA, but there are currently insufﬁcient
ata to recommend other speciﬁc therapies. Available
ata regarding plasma exchange for treatment of post-
ransplantation TMA indicate poor results compared
ith those observed with de novo TTP. Although
here are anecdotal reports of patients who seem to
espond to plasma exchange, randomized controlled
tudies are lacking, and the efﬁcacy of this treatment
as not been clearly borne out in the literature. As
hown in Table 3, which lists published series con-
aining 5 or more patients with posttransplantation
MA treated with plasma exchange, response rates
re generally less than 50%, and mortality rates
mong patients treated with this modality remain
reater than 80%. The committee acknowledges that
he high mortality rates in these series may be skewed
y selection bias because only the sickest patients are
ikely to receive the treatment. For this reason, deter-
ination of any survival beneﬁt attributable to plasma
xchange in the absence of a controlled study is im-
ossible. Given the limited available literature, the
ommittee believes that the universal use of plasma
xchange for posttransplantation TMA cannot be cur-
ently considered the standard of care. The committee
grees that it would be reasonable to substitute corti-
able 3. Response and Mortality for Post-HSCT TMA Treated with
lasma Exchange (PE)
Study
No. Treated
with PE Response Mortality
ilva et al. [17] 8 4 (50%) 7 (88%)
arode et al. [18] 8 3 (38%) 6 (75%)
ua et al. [19] 16 8 (50)% 12 (80%)
lamas et al. [20] 10 8 (80%) 7 (70%)
aquette et al. [21] 7 0 (0%) 7 (100%)
acopino et al. [3] 6 1 (17%) 5 (83%)
derzo et al. [16] 16 (pediatric) NA 7 (44%)
oy et al. [22] 17 3 (18%) 16 (94%)
uge et al. [5] 17 6 (35%) 16 (94%)
uutu et al. [4] 5 4 (75%) 4 (80%)
arkodee-Adoo et al. [23] 11 2 (18%) 9 (82%)
A indicates not available.osteroids or other immune-suppressive agents to pre-
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5ent GVHD as calcineurin inhibitors are discontin-
ed. Whether corticosteroids have beneﬁts in treating
MA is unknown.
ONCLUSIONS
TMA is an underrecognized but potentially dev-
stating complication of allogeneic HSCT. We pro-
ose uniform diagnostic criteria to monitor this com-
lication in all BMT CTN trials. These include RBC
ragmentation, increased LDH, concurrent renal
nd/or neurologic dysfunction (without other expla-
ations), and negative direct and indirect Coombs test
esults. In the absence of deﬁnitive trials, we recom-
end that plasma exchange not be considered a stan-
ard of care for TMA. These recommendations are
ntended to facilitate the identiﬁcation and reporting of
his difﬁcult complication after HSCT and to facilitate
uture clinical studies for its prevention and treatment.
PPENDIX
The BMT CTN was established in October 2001
ith the primary mission of conducting large multi-
nstitutional clinical trials to advance the ﬁeld of he-
atopoietic stem cell transplantation. It is a network
omposed of a core of 16 clinical medical centers that
erform stem cell transplantation across North Amer-
ca and is funded by the National Heart, Lung and
lood Institute and National Cancer Institute divi-
ions of the U.S. National Institutes of Health. The
ata Coordination Center, which coordinates data
ollection and facilitates the administrative activities
f the CTN, is composed of the International Bone
arrow Transplantation Registry/Autologous Bone
Marrow Transplant Registry, National Marrow
onor Program, and EMMES Corporation. The tox-
city committee of the BMT CTN is composed of a
anel of Data Coordination Center representatives
nd transplant physicians from core medical institu-
ions of the CTN. The toxicity committee convenes
n a regular basis to review clinical trials conducted
hrough the CTN and provides guidelines for facili-
ating the identiﬁcation and reporting of transplant
oxicity that occurs on these trials. Additional infor-
ation on the BMT CTN may be found on the BMT
TN Web site at http://www.bmtctn.net.
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